Cell4Cure AB, a Swedish biotech company is pioneering immune tolerance therapies aimed at addressing significant clinical challenges such as anti-drug antibodies (ADAs), autoimmune diseases, and transplant rejection. The company’s proprietary platform leverages ex vivo-generated dendritic cells (DCs) engineered to induce antigen-specific immune tolerance. These tolerogenic DCs offer a targeted approach to mitigating unwanted immune responses while preserving essential immune functions.

Cell4Cure’s primary focus is on Anti-Drug Antibodies (ADAs), a critical issue in conditions like severe hemophilia A, where 30% of patients develop neutralizing antibodies against factor VIII (FVIII) treatments. With our lead product, ItolDC-028, we are ready to initiate a Phase 1/2a clinical trial in Europe to evaluate its safety and efficacy in hemophilia A patients with ADAs. This innovative therapy aims to restore responsiveness to FVIII, providing an alternative to conventional immune tolerance induction therapies.